Centro De Inmunologia Molecular

Centro De Immunologia Molecular

Centro De Inmunologia Molecular (cim)

Luis Enrique Fernández Molina

Circe Mesa Pardillo

Audry Fernández Gómez

Belinda Sánchez Ramírez

Jesús Arturo Junco Barranco

Narjara González Suárez

Lisset Chao García

Mabel Cruz Rodríguez

Diana Rosa Hernández Fernández

Ángel Alexis Manso Vargas

Blanca Idelmis Tolón Murguía

Miguel Antonio López López

Vicente Guillermo Verez Bencomo

Gretchen Bergado Báez

Dayana Pérez Martínez

Maura Lisett Rábade Chediak

Rolando Perez Rodriguez

Kalet León Monzón

Giselle Hevia Hernández

Orlando Valdés Guerrero

Idelmis Curbelo Haredia

María Caridad Rubio Hernández

Tays Hernández García

Leslie Pérez Ruíz

Lourdes Hernández De La Rosa

Eduardo Raul Suarez Pestana

Maria Eliana Lanio Ruiz

Rady Judith Laboroe Quintana

Yoelys Cruz Leal

Maria Del Carmen Luzardo Lorenzo

Carlos Manuel Alvarez Valcárcel

Isabel Fabiola Pazos Santos

Mayra Tejuca Martínez

Aisel Valle Garay

Maria Eugenia Alonso Biosca

Liem Canet Santos

Elias Antonio Gracia Medina

Anabel De La Barrera Aira

Joel De Leon Delgado

Yildian Diaz Rodriguez

Liliana Oliver Ríos

Rydell Alvarez Arzola

Vladimir Peña Sánchez

Camilo Rodríguez Rodríguez

Anet Valdés Zayas

Lena Aguiar García

This invention describes ways of obtaining nano-particulated adjuvants formed by different synthetic variants of GM3 ganglioside. Depending on the fine structure of the fatty acid in the ceramide of the synthetic GM3, said adjuvants are able to stimulate specifically and in a specialized way the humoral or cellular immune response against accompanying antigens. Particularly, this invention provides immunogenic vaccine compositions that comprise peptides, polypeptides or proteins and the aforementioned nanoparticles, which are formed through the dispersion of hydrophobic proteins of the outer membrane complex (OMC) ofin solutions containing fully synthetic variants of the GM3 ganglioside.

Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines

The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.

Fusion proteins composed of an interleukin-2 mutein and type I interferon

The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles ofand the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.

Ganglioside GM3-containing nanoparticles as immunomodulators

The present invention relates to the field of biotechnology applied to human health. The invention describes a vaccine vehicle which toxins from eukaryotic organisms are encapsulated in liposomes with multiple lipid layers, obtained by means of the process of dehydration/rehydration, the lipid composition of which is dipalmitoylphosphatidylcholine:cholesterol in a molar ration of 1:1, which are designed for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. The compositions described allow modulation of the specific CTL immune response to one or more antigens co-encapsulated in the liposomes that containing the toxin. The vaccine vehicle of the present invention presents advantages as compared with others described in the prior art owning to the robust and functional nature of the immune response induced and also the immunomodulating properties thereof.

Vaccine composition based on sticholysin encapsulated into liposomes

Vaccine compositions in which gangliosides and the OMP ofwere combined to form very small size proteoliposomes (VSSP) to be administered subcutaneously are described, these compositions do not require the use of any additional adjuvant. The described compositions allow the immunological treatments with gangliosides, particularly N-AcGM3/VSSP and N-GcGM3/VSSP, showing advantages due to the less aggressive reaction in the site of injection and can be used in a simpler way and better for the patients.

Ganglioside based vaccine compositions for subcutaneous administration

This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes. The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) ofwith gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized. The essence of the invention consists in describing compositions that triggers immunogenicity in low immunogenic antigens, such as growth factor receptors, without imparting structural changes therein. Particularly, this invention refers to preparation of immuno-stimulating compositions capable of generating antigen-specific immune responses, even in immuno-compromised hosts, such as those suffering form cancer or viral or bacterial chronic infections. In said patients, the administration of the vaccine compositions described in this invention has lead to the reestablishment of the functionality of the immune system. Vaccine compositions of this invention can be used to protect or treat infectious, or auto-immune diseases.

Preparations that potentiate immunogenicity in low immunogenic antigens

Growing community of inventors

Havana, Cuba

Luis Enrique Fernández Molina